Treatment Intensification With Temozolomide in Adults With a Glioblastoma

To join this study, you need to be at least 18 years old and have been recently diagnosed with a **newly developed** glioblastoma. This diagnosis must be confirmed by a doctor after surgery or a biopsy. You should also be well enough to take part, meaning you can generally look after yourself, even if you have some weakness from the tumour. Your body should also be working well enough, as checked by blood tests.

There are also some reasons why you might not be able to join. For example, if your glioblastoma has come back after treatment, or if you've had certain other cancers recently. You also can't be pregnant or breastfeeding, or have certain other serious medical conditions like a recent severe blood disorder or specific infections like HIV or hepatitis. Your doctors will go through all these details carefully with you to see if the study is a good fit.

If you decide to take part in this study, you would first sign a consent form, showing you understand and agree to participate. You would then be assigned to one of two treatment groups by chance (like flipping a coin). One group will receive the standard treatment for glioblastoma, which involves radiation therapy and the chemotherapy drug temozolomide (TMZ), followed by six cycles of TMZ.

The other group will receive an intensified treatment. This means you would receive TMZ earlier and continue it for a longer period of time, unless you experience significant side effects, your cancer progresses, or you decide to stop the treatment. Both groups will receive radiation therapy. You will have regular appointments with your study doctors and nurses, including check-ups, blood tests, and scans, to monitor your health and how the treatment is working. The total length of your participation would depend on your treatment plan and how you respond to it, potentially continuing for several months or longer while on TMZ and for follow-up.